T
Thomas F. Lüscher
Researcher at University of Zurich
Publications - 1613
Citations - 88517
Thomas F. Lüscher is an academic researcher from University of Zurich. The author has contributed to research in topics: Endothelium & Myocardial infarction. The author has an hindex of 134, co-authored 1560 publications receiving 79034 citations. Previous affiliations of Thomas F. Lüscher include University of Texas Southwestern Medical Center & Durham University.
Papers
More filters
Proceedings ArticleDOI
2003 European society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension
Giuseppe Mancia,Enrico Agabiti Rosei,Renata Cifkova,G DeBacker,Serap Erdine,Robert Fagard,Csaba Farsang,Antony M. Heagerty,K Kawecka-Jaszcs,Wolfgang Kiowski,Sverre E. Kjeldsen,Thomas F. Lüscher,Gordon T. McInnes,Jean-Michel Mallion,Eoin O. Brien,Neil Poulter,Silvia G. Priori,Karl Heinz Rahn,Jose L. Rodicio,L. Ruilope,M. E. Safar,Jan A. Staessen,P. A. Van Zwieten,Bernard Waeber,Bryan Williams,Alberto Zanchetti,Faiez Zannad +26 more
TL;DR: The Committee has tried to avoid giving rigid rules that would constrain judgement on the management of individual patients differing in their personal, medical and cultural characteristics.
Journal ArticleDOI
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial
Murray D. Esler,Henry Krum,Paul A. Sobotka,Markus P. Schlaich,Roland E. Schmieder,Michael Böhm,Felix Mahfoud,Horst Sievert,Nina Wunderlich,Lars Christian Rump,Oliver Vonend,Michael Uder,Mel Lobo,Mark J. Caulfield,Andrejs Erglis,Michel Azizi,Marc Sapoval,S. Thambar,Alexandre Persu,Jean Renkin,Heribert Schunkert,Joachim Weil,Uta C. Hoppe,Tony Walton,Dierk Scheinert,Thomas Binder,Andrzej Januszewicz,Adam Witkowski,Luis M. Ruilope,Robert Whitbourn,Heike Bruck,Mark Downes,Thomas F. Lüscher,Alan G. Jardine,Mark Webster,Thomas Zeller,Jerzy Sadowski,Krzysztof Bartus,Craig A. Straley,Neil C. Barman,David P. Lee,Ronald M. Witteles,Vivek Bhalla,Joseph M. Massaro +43 more
TL;DR: Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients and should be continued, according to the authors.
Journal ArticleDOI
Diabetes and Vascular Disease Pathophysiology, Clinical Consequences, and Medical Therapy: Part I
TL;DR: The present review will focus on the relationship of diabetes mellitus and atherosclerotic vascular disease, highlighting pathophysiology and molecular mechanisms (Part I) and clinical manifestations and management strategies (Part II).
Journal ArticleDOI
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy
Christian Templin,Jelena R. Ghadri,Johanna Diekmann,L. Christian Napp,Dana Roxana Bataiosu,Milosz Jaguszewski,Victoria L. Cammann,Annahita Sarcon,Verena Geyer,Catharina A. Neumann,Burkhardt Seifert,Jens P. Hellermann,Moritz Schwyzer,Katharina Eisenhardt,Josef Jenewein,Jennifer Franke,Hugo A. Katus,Christof Burgdorf,Heribert Schunkert,Christian Moeller,Holger Thiele,Johann Bauersachs,Carsten Tschöpe,Heinz-Peter Schultheiss,Charles A. Laney,Lawrence Rajan,Guido Michels,Roman Pfister,Christian Ukena,Michael Böhm,Raimund Erbel,Alessandro Cuneo,Karl-Heinz Kuck,Claudius Jacobshagen,Gerd Hasenfuss,M. Karakas,M. Karakas,Wolfgang Koenig,Wolfgang Koenig,Wolfgang Rottbauer,Samir M. Said,Ruediger C. Braun-Dullaeus,Florim Cuculi,Adrian P. Banning,Thomas Fischer,Tuija Vasankari,K.E. Juhani Airaksinen,Marcin Fijałkowski,Andrzej Rynkiewicz,Maciej Pawlak,Grzegorz Opolski,Rafal Dworakowski,Philip MacCarthy,Christoph Kaiser,Stefan Osswald,Leonarda Galiuto,Filippo Crea,Wolfgang Dichtl,Wolfgang-Michael Franz,Klaus Empen,Stephan B. Felix,Clément Delmas,Olivier Lairez,Paul Erne,Jeroen J. Bax,Ian Ford,Frank Ruschitzka,Abhiram Prasad,Thomas F. Lüscher +68 more
TL;DR: Patients with takotsubo cardiomyopathy had a higher prevalence of neurologic or psychiatric disorders than did those with an acute coronary syndrome and physical triggers, acute neurologics or psychiatric diseases, high troponin levels, and a low ejection fraction on admission were independent predictors for in-hospital complications.
Journal ArticleDOI
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency.
Stefan D. Anker,Josep Comin Colet,Gerasimos Filippatos,Ronnie Willenheimer,Kenneth Dickstein,Helmut Drexler,Thomas F. Lüscher,Boris Bart,Waldemar Banasiak,Joanna Niegowska,Bridget Anne Kirwan,Claudio Mori,Barbara von Eisenhart Rothe,Stuart J. Pocock,Philip A. Poole-Wilson,Piotr Ponikowski +15 more
TL;DR: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable.